medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 6

<< Back Next >>

Ann Hepatol 2017; 16 (6)

The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population

Martínez LA, Larrieta E, Calva JJ, Kershenobich D, Torre A

Language: English
References: 24
Page: 909-915
PDF size: 315.03 Kb.


ABSTRACT

Background. Nonalcoholic fatty liver disease (NAFLD) encompasses: fatty liver (SS), steatohepatitis (NASH) with or without fibrosis and cirrhosis. Patatine-like phosphatas in domain 3 (PNPLA3; adiponutrin; SNP rs738409 C/G, M148I) shows anabolic and catabolic activities on lipid metabolism and significant association to fatty liver content; however, I148M demographics and ethnics, as its role with NAFLD have not been fully elucidated. Material and methods. PNPLA3 genotyping from peripheral blood DNA by polymerase chain reaction (PCR) and direct sequencing, 211 patients diagnosed with NAFLD including SS, NASH and fibrosis spectrum. Results. Eighty nine per cent showed the G risk allele [CC: 23 (10.5%), GC: 73 (34.7%), GG 115 (54.7%)], the allele frequency was 77%, NASH (71%), SS (80%) and fibrosis (73%). GG genotype carriers showed 3.8 times (CI 95%: 3.03 - 4.79) of increased risk of steatohepatitis and 2.3 times more (CI 95%: 1.77 ~ 3.23) risk of having liver fibrosis (CC). PNPLA3 (GC, GG) conditioned higher probability of low levels of HDL cholesterol (p ‹ 0.010), SS even in normal weight (p ‹ 0.007), insulin resistance by HOMA (p ‹ 0.029), NAFLD fibrosis score showed › 0.675 (p ‹ 0.001) and altered serum alanine aminotransferase (p ‹ 0.05). Conclusion. PNPLA3 expression in Hispanics could be decisive in NAFLD pathogenesis, it's highly prevalent and it's a key to condition and determine the spectrum associated, SS, NASH and fibrosis.


REFERENCES

  1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592–609.

  2. Méndez-Sánchez N, Villa A, Chávez-Tapia N, Ponciano-Rodriguez G, Almeda-Valdés P, González D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Annals of Hepatology 2005; 4: 52-5.

  3. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.

  4. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics 2008; 40: 1461-5.

  5. Stefano R, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the Pathogenesis of Fatty Liver Disease: Patatin-like Phospholipase Domain-Containing 3 Protein. Current opinion in lipidology 2010; 21: 247-52.

  6. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS genetics 2011; 7: e1001324.

  7. Qiao A, Liang J, Ke Y, Li C, Cui Y, Shen L, Zhang H, et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 2011; 54: 509-21.

  8. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-4.

  9. Gutierrez-Grobe Y, Villalobos-Blasquez I, Canizales-Quinteros S, Dominguez-Lopez A, Sanchez-Muñoz F, García-Corona C, Uribe M, Méndez-Sánchez N, et al. A PNPLA3 Gene Polymorphism is Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Mexican Patients. Gastroenterology 2010; 138: S-803.

  10. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2011; 33: 525-40.

  11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.

  12. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-53.

  13. Alberti KMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120; 16: 1640-5.

  14. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.

  15. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007; 102: 2716-7.

  16. Lee S, Jin Kim Y, Yong Jeon T, Hoi Kim H, Woo Oh S, Park Y, Soo Kim S. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study. Scand J Gastroenterol 2006; 41: 566-72.

  17. Nobili V, Corte CD, Monti L, Alisi A, Feldstein A. The use of ultrasound in clinical setting for children affected by NAFLD: is it safe and accurate? Ital J Pediatr 2011; 37: 36.

  18. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007; 11: 37-54, viii.

  19. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, Repetto G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14: 635-7.

  20. Bloomer JR, Goodman ZD. Clinical and pathological correlations in liver disease: approaching the next Milennium. Chica go, Illinois: AASLD Postrgraduate Course; 2008, p. 187-93.

  21. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez- Bermejo M, Majano PL, Apolinario A, Larranaga E, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-24.

  22. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008; 31: 562-8.

  23. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.

  24. Larrieta-Carrasco E, Leon-Mimila P, Villarreal-Molina T, Villamil- Ramirez H, Romero-Hidalgo S, Jacobo-Albavera L, Gutierrez- Vidal R, et al. Association of the I148M/PNPLA3 variant with elevated alanine transaminase levels in normal-weight and overweight/obese Mexican children. Gene 2013; 520: 185-8.




2020     |     www.medigraphic.com